{"id":685811,"date":"2024-01-25T16:04:01","date_gmt":"2024-01-25T16:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685811"},"modified":"2024-01-25T16:04:01","modified_gmt":"2024-01-25T16:04:01","slug":"galapagos-nvs-filgotinib-market-size-expansion-of-several-folds-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/galapagos-nvs-filgotinib-market-size-expansion-of-several-folds-by-2030_685811.html","title":{"rendered":"Galapagos NV\u2019s Filgotinib Market size expansion of Several Folds by 2030"},"content":{"rendered":"
\"Galapagos<\/a><\/div>\n
ilgotinib (Galapagos NV) providing insights into the drug market landscape and market forecast of Filgotinib upto 2030.<\/div>\n

[Las Vegas, United States] DelveInsight,<\/strong> a leader in healthcare research firm, has recently published an in-depth report on Filgotinib (Galapagos NV)  providing insights into the drug market landscape and market forecast of Filgotinib upto 2030. The report, titled “Filgotinib Market Size, Forecast, and Emerging Insight – 2030” is now available for review and analysis.<\/p>\n

 <\/p>\n

Are you interested in finding out the projected market size of Filgotinib in 2032? Filgotinib Market Forecast<\/a><\/strong><\/p>\n

 <\/p>\n

The Filgotinib Market Report offers projected sales forecasts for Filgotinib for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of  competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.<\/p>\n

 <\/p>\n

Galapagos NV’s Filgotinib<\/strong> is serving as a beacon of hope for the patients suffering from the Rheumatoid Arthritis. <\/p>\n

 <\/p>\n

What is Filgotinib Prescribed for?<\/strong><\/p>\n

Filgotinib, known as Jyseleca®<\/strong>, is an oral Janus kinase (JAK) inhibitor sanctioned for the management of moderate to severe active rheumatoid arthritis (RA) in adults. It is endorsed either as a standalone treatment or in conjunction with methotrexate for individuals who exhibit inadequate responses or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).<\/p>\n

The report extensively covers the details and developments related to Filgotinib, capturing important highlights on developmental pipeline, regulatory status and special designations of Filgotinib, route of administration, safety and efficacy details.<\/p>\n

 <\/p>\n

Filgotinib Market Assessment<\/strong><\/p>\n

This report provides a detailed market assessment of Filgotinib for Rheumatoid Arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.<\/p>\n

 <\/p>\n

Filgotinib Clinical Assessment<\/strong><\/p>\n

The report provides the clinical trials information of Filgotinib for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related. <\/p>\n

 <\/p>\n

Do you know your drug’s competitive positioning against Filgotinib? Filgotinib Drugs Insights<\/a><\/strong><\/p>\n

 <\/p>\n

Filgotinib Competitive Landscape<\/strong> <\/p>\n

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Filgotinib.<\/p>\n

 <\/p>\n

Filgotinib Market Size in the US<\/strong><\/p>\n

A dedicated section of the report focuses on the expected market size of Filgotinib for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.<\/p>\n

Filgotinib (sold under the brand name Jyseleca®) is authorized for use either alone or in conjunction with methotrexate for managing moderate to severe active rheumatoid arthritis (RA) in adults experiencing inadequate responses or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).<\/p>\n

 <\/p>\n

Key Highlights of Filgotinib: <\/strong><\/p>\n